Canadian Private Placements: A Deal Lawyer's Guide to Structure, Control and Closing Risk

Since 2020, I have worked on over 100 brokered and non-brokered private placements across the Canadian capital markets ecosystem, first alongside senior counsel at other firms and later as a lawyer. That kind of volume teaches you quickly where private placements work, and where they start to wobble.

Private placements, also called exempt market financings, are often sold as the simpler and cheaper alternative to a prospectus offering. Sometimes they are, but the bigger misconception is that they are easy money. They are not difficult because the law is conceptually complicated. They are difficult because timing, control, dilution, exchange policy, settlement plumbing, and disclosure discipline all collide at once. That collision matters to exactly the people who tend to live around these deals: issuers, funds and deal teams, founders and owner-operators of public and late-stage private issuers, fund principals, dealers and active allocators, strategic insiders, control holders and serial deal sponsors, and boards and management teams navigating exchange-sensitive financings. If you sit in that world, you already know that the legal structure is only half the transaction; the other half is execution.

This guide is written with that audience in mind. It is broad enough to be useful to people coming up the curve, but it is not meant to be a rookie primer. The goal is practical judgment. If you already know the difference between a prospectus exemption and a dealer registration exemption, the sections that usually contain the real gold are the ones on brokered versus non-brokered deals, insider participation and control thresholds, exchange process, DAP settlement, treasury directions, and use of proceeds.

One distinction is worth getting straight at the outset. A prospectus exemption and a dealer registration exemption are not the same thing. Even where a valid prospectus exemption exists, the dealer-registration analysis still matters, because a person in the business of trading securities may need to be registered or otherwise exempt.

At the highest level, Canadian securities law starts from a simple premise: a distribution of securities generally cannot be made unless a prospectus has been prepared, filed with the relevant regulator, and receipted, unless a valid exemption is available. A prospectus requires full, true and plain disclosure of all material facts, and that is expensive, time-consuming work. That is why private placements remain the alternative workhorse.

A private placement, formally an exempt distribution, is a distribution of securities made in reliance on one or more statutory prospectus exemptions, typically to a narrower universe of purchasers. It usually offers less regulatory review, less cost and more speed than a prospectus offering, but the trade-off is real: the securities are subject to resale restrictions, the investor pool is more limited, and the documentation still has to be right.

An issuer is any person or company that has issued, or proposes to issue, a security. A reporting issuer is generally an issuer that has become subject to ongoing public disclosure obligations in Canada. That often happens through a prospectus, but not only through a prospectus. An issuer can become a reporting issuer through other routes, including certain listing-related transactions, RTO structures and similar pathways.

A reporting issuer may or may not be listed on a stock exchange. That distinction matters. A reporting issuer with no exchange listing still carries continuous disclosure obligations, while a listed issuer carries both securities law obligations and exchange policy obligations. By contrast, a non-reporting issuer usually has a much lighter ongoing disclosure burden, but it still has to get the exempt market analysis right when it raises capital.

Four structural variables usually shape the legal and process analysis for a Canadian private placement:

• whether the issuer is a reporting issuer or a non-reporting issuer;
• whether the issuer is listed on a stock exchange such as the CSE, TSXV or TSX;
• whether the issuer, the dealer or the investors bring in cross-border considerations; and
• whether the offering is brokered, non-brokered or underwritten.

Sophisticated participants care about these variables because they drive far more than disclosure. They determine who can invest, what paper needs to be signed, how flexible pricing really is, what resale restrictions attach, whether exchange approvals get ugly, whether insider or control issues appear, and how much post-closing cleanup waits on the other side.

In other words, the exemption mix is not just legal plumbing. It shapes the approval path, the investor pool, the financing timeline and, in some cases, the control map of the issuer. That is why good deal teams do not treat a private placement as an isolated financing. They treat it as part of a larger capital formation strategy.

National Instrument 45-106 consolidates the principal prospectus exemptions used in Canadian private placements. In the real world, one financing often relies on multiple exemptions at once. A common structure will accommodate institutional accounts under the accredited investor exemption, strategic individuals under family, friends and business associates, and foreign investors under their own local exemptions, often including Regulation D or Regulation S in the United States.

Canada still has no single national securities regulator. Each province and territory has its own securities commission and Securities Act, while the Canadian Securities Administrators coordinate national instruments. In a typical private placement, the main regimes in play include provincial securities acts, exempt distributions (NI 45-106), resale restrictions (NI 45-102), continuous disclosure (NI 51-102), early warning and take-over bids (NI 62-103 and NI 62-104), institutional settlement (NI 24-101), and insider reporting (NI 55-104).

On top of securities law, the stock exchanges bring their own rulebooks. The CSE, TSXV and TSX each impose their own pricing rules, notice requirements, approval thresholds, forms and closing conditions. Corporate law also matters. The constating documents have to authorize the securities being issued, and boards need to approve the transaction properly. If there are pre-emptive rights, shareholder agreement mechanics, special rights, or conflict issues, those need to be identified before launch, not discovered when the signatures are already in flight.

The split between brokered and non-brokered deals drives a lot more than who is making introductions. In a non-brokered private placement, the issuer raises directly from investors without a dealer formally leading the book. While that can look leaner and faster on paper, issuers have limited room to solicit investment, usually have far less access to institutional capital and active market participants, and in practice often end up drawing from a much narrower pool of existing contacts, strategic relationships, friends, family and business associates.

In a brokered private placement, one or more registered Exempt Market Dealers (EMDs) act as agents or underwriters, help with structure and pricing, market the deal, and usually get paid cash commissions plus broker paper, often broker warrants or similar entitlements. The dealer brings reach, market access, distribution capability, pricing discipline and a compliance framework that can materially improve the quality and execution of the financing. That does mean a more formal process, with fuller documentation, internal compliance steps, heightened AML/KYC and dealer counsel involvement, but in a well-run deal those are usually features rather than bugs and can materially reduce execution risk for the issuer, including by improving investor screening, pricing discipline, book quality, document accuracy and overall closing coordination.

Either structure can work for issuers and for investment funds. The right answer usually depends on the investor base, the size of the raise, the urgency of the financing, and whether the issuer is trying to solve a straight capital need or a more strategic problem around price, distribution and control.

The accredited investor definition in NI 45-106 covers institutions as well as individuals. For individuals, the categories most often used in operating-company financings are the financial assets test, the income test and the net assets test. The key practical point is that the category actually relied on matters. It should be captured accurately in the subscription package and reflected correctly in Form 45-106F1.

Eligible investor is a different concept, used primarily in the offering memorandum context, with different thresholds. It is not interchangeable with accredited investor. Likewise, private issuer status can be convenient but it is fragile. Once a non-reporting issuer sells outside the permitted purchaser universe, or otherwise loses private issuer status, it does not get to casually put that toothpaste back in the tube.

Depending on the sector and transaction, other exemptions can matter a lot. Asset acquisition exemptions, petroleum, natural gas and mining property exemptions, additional investment in investment funds, existing security holder exemptions, start-up crowdfunding under NI 45-110 and the listed issuer financing exemption (LIFE) all have their place. In mining and venture land in particular, these are not academic side-notes. They often shape how quickly an issuer can move and what kind of investor mix it can tolerate.

For listed reporting issuers that need speed and broader access to the market, LIFE has become a strategic asset. But it is not magic. There's more to life than LIFE. It works best when the issuer's continuous disclosure record is clean, current and disciplined. Sloppy disclosure before launch tends to become expensive disclosure during launch. Baseline LIFE limits permit an issuer to raise the greater of $5 million and 10% of its market capitalization, to a maximum of $10 million, in any 12-month period, subject to the applicable dilution cap. Since May 2025, issuers in jurisdictions adopting Coordinated Blanket Order 45-935 have, in appropriate cases, been able to rely on increased limits to raise the greater of $25 million and 20% of the issuer's aggregate market value, to a maximum of $50 million in any 12-month period, subject to the order's conditions and modified dilution mechanics. In other words, LIFE can be fast and useful, but it is still not a free-for-all.

A private placement is fundamentally different from a public prospectus offering, even when the issuer is already listed on the TSX or TSXV. In a public offering, once a prospectus is receipted, securities are generally sold into a wider market and are typically freely tradeable on issue, subject to any other applicable restrictions. In a private placement, the investor universe is narrower, documentation is negotiated privately, and resale restrictions usually attach.

Many transactions structured as private placements also resemble PIPEs, private investments in public equity. That is especially true where a public issuer privately places securities with one or more strategic or institutional investors in connection with a broader acquisition, royalty, option, restructuring or governance play. At that point, the financing is no longer just a financing but also part of the transaction architecture.

One point that gets left too late far too often is compensation. If there are any finders, dealers or strategic introducers in the deal, the economics need to be clear at the term-sheet stage: cash commission, corporate finance fee, advisory fee, broker warrants, agent's options, finder shares, finder warrants, and who is being paid on which accounts. If you leave that until the subscription round is underway, you are inviting a late fight over net proceeds, disclosure, exchange filings and closing mechanics.

This matters not only because compensation affects net proceeds, but also because it affects dilution, control and the approval path. In thinly capitalized juniors, a large dealer or finder fee package paid in securities or warrants is not just compensation. It is future paper. And future paper can become future leverage.

The CSE directly asks for it in Form 9. On the TSXV, this is not a footnote. Form 4B specifically asks for any commission, finder's fee or similar payment connected to the private placement, whether in cash, securities or other consideration, and TSXV Policy 5.1 requires advance notice and exchange acceptance of finder's fees and commissions. Policy 5.1 also contains technical rules around commission warrants and the valuation of securities-based compensation. The practical lesson is simple: fee economics are part of the deal structure, not end-of-process garnish.

Before launch, the board should confirm corporate authority, approve the financing structure, and identify whether any additional approvals are needed. Where directors, officers or significant shareholders are participating, conflict-of-interest analysis can arise under corporate law, securities law and exchange policy. On the TSX and TSXV, MI 61-101 and related-party transaction concepts can also come into view depending on the facts.

In practice, I treat overlapping-role situations as a term-sheet problem, not a closing problem. If a director of Issuer A is also a director or officer of Issuer B, and the financing proceeds are going to fund a transaction involving Issuer B, the conflict should be disclosed conspicuously, not buried in boilerplate. Conspicuous is the operative word.

That is especially true where the use of proceeds is tied to a royalty deal, option agreement, SAFE, warrant structure, asset purchase or inter-issuer relationship. If the same people are effectively sitting on both sides of the transaction, the disclosure should say so clearly and early. Buried conflict disclosure is how you create financing risk, board risk and ugly follow-up questions after launch.

This is the part of the article that sophisticated readers usually care about most, because this is where a financing stops being just a raise and starts becoming a leverage event.

Under provincial securities acts, insiders generally include directors, officers and persons or companies that beneficially own, directly or indirectly, more than 10% of the voting securities of a reporting issuer. Under exchange policy, the vocabulary broadens. On the TSXV and TSX, terms such as Insider, Control Person, Principal and Pro Group drive pricing, disclosure, exchange hold periods and shareholder approval analysis. These frameworks do not line up perfectly, which is why parallel analysis matters.

At a high level, an early warning report and news release are required when a person or company acquires beneficial ownership of, or control or direction over, 10% or more of a class of voting or equity securities of a reporting issuer, subject to the lower 5% threshold in a take-over bid context. Subsequent early warning disclosure is generally required for every 2% increase or decrease in the holdings of a 10% holder, for material changes in a prior report, and if the holder drops below the 10% threshold. Also, once the early warning trigger has been hit and the required news release has gone out, there is generally a one business day cooling-off period after filing before additional acquisitions of that class can be made.

Where practitioners still need to be careful is passive dilution. If a holder does not buy or sell but its percentage moves because new paper is issued around it, do not make lazy assumptions near thresholds. If the percentage is moving meaningfully, treat it as a live issue before closing, not a post-closing shrug.

Insiders of reporting issuers also need to think about insider reporting under NI 55-104 and SEDI. That filing burden is different from early warning, but in live financings the two often end up being checked off the same cap-table and closing checklist.

Control is the primary lever here. A private placement can shift influence, create or eliminate control blocks, force or avoid shareholder approvals, trigger early warning or insider reporting, and change future negotiating leverage. That is why serious deal people obsess over who is participating, at what price, through what vehicle, on what basis, and what the post-closing chart looks like.

Sometimes the change is obvious. A new strategic investor is about to become a Control Person. Sometimes it is quieter. A whale tops up just enough to preserve influence while everyone else is diluted. A dealer or finder ends up with enough fee paper to matter later. Friendly money comes in through multiple accounts and the post-closing map looks nothing like the launch call. This is the stuff that determines who really has room to move after the financing closes.

A live cap table is not admin. It is the control dashboard. Throughout a private placement, I track holdings on three bases: undiluted, partially diluted and fully diluted.

• Undiluted means outstanding common shares only.
• Partially diluted usually means common shares plus some subset of convertible or issuable securities (e.g. warrants) being analyzed for the particular purpose.
• Fully diluted means the full stack of outstanding options, warrants, convertible debentures and similar rights.

On the TSXV, Form 4B expressly requires disclosure of holdings on both undiluted and diluted bases and flags placees that hit 5% or more post-closing, which is one more reason the cap table has to be live. In practice, the cap table is often the first document that tells you whether the financing is becoming control-sensitive, whether a corporate placee form is required, whether a new insider is being created, or whether a threshold problem is about to land on your desk. If you are not updating the cap table every time the investor list changes, you are not really running the financing. You are guessing.

TSXV Policy 4.1 remains the daily reality for a huge slice of the Canadian venture market. The process starts with price reservation, either through a comprehensive news release or, where permitted, a Form 4A price reservation filing. Within 30 days of the price reservation date, the issuer files Form 4B and seeks conditional or final acceptance. If only conditional acceptance is obtained, closing can occur on that basis only where the policy and acceptance terms permit it. Final information then needs to be filed, and the TSXV bulletin follows once final acceptance and closing are in place. For timing purposes, Policy 4.1 also puts a real clock on the financing. Non-brokered placements generally must close within the greater of 15 days from Conditional Acceptance and 45 days from the Price Reservation Date. Brokered placements generally get the greater of 30 days from Conditional Acceptance and 60 days from the Price Reservation Date, unless the TSXV consents otherwise.

The tactical point is that Form 4B is not just a cover sheet. It asks whether the financing will create a Control Person, whether placees are insiders or part of the Aggregate Pro Group, whether corporate placee forms are needed, and what compensation is being paid to brokers, agents or finders. If you wait until the final placee list to think about those questions, you are already late.

TSXV private placements become shareholder-approval sensitive quickly when a Control Person is being created or where insider and Pro Group participation becomes meaningful. The exact thresholds and facts matter, and venture issuers should resist the temptation to apply folklore instead of the actual policy.

TSX practice is different enough that issuers should not treat it as dressed-up TSXV practice. Section 607 defines private placements for TSX purposes, and the notice to TSX is made through Form 11. Depending on the deal, that filing can be handled on an expedited or regular basis. Certain placements that are at or above market price, or that are within the permitted discount and not overly dilutive, are generally processed more quickly. More complex, more dilutive or more insider-sensitive deals get a fuller review.

TSX also builds real mechanics into the process. Section 607 allows price protection through Form 11A, and successive private placements may be aggregated in certain circumstances. Warrants and convertible securities also matter to the dilution analysis. That matters because a financing that looks manageable on a headline common-share count can look much more aggressive once the whole stack is counted.

At a high level, TSX securityholder approval becomes a real issue for discounted highly dilutive placements and for certain insider-heavy placements. Section 607(g), for example, requires approval for certain highly dilutive placements, including those that exceed 25% of the outstanding listed securities on a non-diluted basis, and for certain insider issuances over a six-month period that exceed the 10% threshold. That is exactly why TSX financings need to be modeled early, not blessed at the back end.

The CSE has become more technical and more operationally structured than people sometimes assume. Policy 6 defines a private placement as a prospectus-exempt distribution for cash or for forgiveness of bona fide debt, applies pricing rules, and ties private placements back into securityholder approval concepts under Policy 4.

For most CSE private placements, the issuer needs to announce the financing and post Form 9, the Notice of Proposed Issuance of Listed Securities, before closing. On closing, the issuer must post the final Form 9 and a signed Certificate of Compliance, and then deliver the required closing support, including counsel opinion and confirmation that the applicable resale restriction, including any Exchange Hold, has been imposed.

Form 9 still needs to line up with the financing terms, the placee list, the fee disclosure, the hold analysis and the closing mechanics. Policy 6 ties listed securities issued in connection with a private placement to the CSE Hold framework, subject to the policy's exceptions and any exchange approval. So even on a market that some people still describe as more flexible, the hold analysis, disclosure timing and closing paperwork still need to be right. Having said that, the CSE's policy burden is often lower than that of the TSX or even the TSXV.

Securities acquired under most capital-raising exemptions are subject to resale restrictions under NI 45-102. If the issuer is a reporting issuer on the distribution date, the familiar four months and one day hold applies. If the issuer is not a reporting issuer on the distribution date, the resale analysis becomes much more restrictive. In practice, there is no simple time-based clearance from closing, and the securities can remain effectively locked up unless and until the issuer becomes a reporting issuer or a specific resale exemption is available.

The first trade will generally need to rely on a specific resale exemption under NI 45-102 or another available exemption. Certificates, DRS advices or other accepted book-entry records must reflect the right legend. The date must be computed from the actual distribution date. If the issuer becomes a reporting issuer later, the legend logic changes. For U.S. persons, the U.S. resale legend analysis also has to be layered in properly.

The exchange side matters too. The TSXV still imposes an Exchange Hold Period in specified circumstances, and Policy 3.2 prescribes the legend or corresponding book-entry hold notation for securities subject to that hold. CSE private placements can also attract an Exchange Hold under Policy 6. None of this is clerical trivia. If the legends or hold notations are wrong, incomplete or inconsistent between the shares and the warrants, the problem will usually surface at exactly the worst time.

This is also one place where lawyers should stop talking in abstractions. The issuance package needs to answer three practical questions cleanly: what is the securities law hold, what is the exchange hold, and what foreign resale legend, if any, also applies. If you cannot answer those three questions quickly, the issuance package is not done.

A lot of financings do not go sideways because the term sheet was bad. They go sideways because back office ops, registrations, legends and settlement sequencing were treated like clerical clean-up instead of legal-execution work. This is where the back-office plumbing matters.

Institutional private placement closings in Canada often settle on a delivery-against-payment or receipt-against-payment basis through a custodian and CDS. In practical terms, the executing broker, the carrying broker or custodian, the transfer agent and the issuer's counsel all need to line up on who is delivering what, where it is landing and when the cash is actually moving.

The executing broker or dealer syndicate executes the trade with the issuer or selling agent. The investor's carrying broker or custodian acts as the DAP broker and generally releases payment only once the securities land where they are supposed to land. Settlement is coordinated through CDS for depository-eligible paper, or through physical or other manual delivery mechanics where that is still how the broker wants to receive the securities.

The phrase securities cage still sounds like it belongs in another decade because, in a lot of ways, it does. But it remains a real operational chokepoint. Cage personnel check registrations, legends, account names and delivery mechanics. Some brokers will accept electronic issuance mechanics more comfortably than others. Some still want physical paper or very specific handling for certain instruments. Either way, if the cage is confused, your closing date can become more aspirational than real.

From the issuer's side, the DAP broker is the settlement gatekeeper for institutional investors. DAP brokers hold client accounts, provide registration instructions, coordinate settlement mechanics and, in practice, have zero tolerance for sloppiness in how the paper is registered.

The broker may require registration in a format such as Broker Name ITF Client Name [Account Number], or Broker Name TR Client Name, or another broker-specific variant. ITF and TR are not interchangeable in every case, and some brokers can be maddeningly specific about abbreviations, account numbers and which city or cage location is receiving the paper. If the registration is wrong, the paper can be rejected, re-issued and re-delivered, which can move cash receipt by one or more business days.

Although some DAP brokers do accept electronically executed certificated instruments like warrants and subscription receipts when informed before settlement, many remain uncomfortable with e-signatures and still insist on wet-ink execution. Where the receiving broker insists on physical paper, wet-ink execution and delivery mechanics can become a live closing issue. In practice, that can mean a last-minute scramble for officer signatures at exactly the wrong time, which is another easy way to delay closing.

That is why I treat registration instructions as an early-closing workstream, not a same-day chore, and confirm the broker format, the account details and the delivery point before the treasury direction is finalized.

Transfer agents sit at the centre of the Canadian equity infrastructure. They maintain the official register, process issuances, exercises and transfers, and work from the treasury direction or security issuance direction sent by issuer's counsel. That direction typically sets out the registered name and address, security type and number, legends, U.S. person status, beneficial ownership details and any special instructions.

Accuracy here is non-negotiable. A wrong registration can lead to a cage rejection. A missing legend can create a resale problem. A wrong number can throw off the register and the closing filings. This is why seasoned deal teams try to get the draft treasury direction to the transfer agent at least two to three business days before closing and make the transfer agent part of the QA loop early.

A well-run private placement usually involves, at a minimum, board approvals, a term sheet or summary of terms, the subscription package, any dealer or agency documents, treasury directions, exchange forms, Form 45-106F1 and schedules, and a closing agenda or checklist that allocates responsibility clearly.

The term sheet deserves more respect than it often gets. It should not just cover price, size and securities. It should also address who is placing the deal, whether there are any cash commissions, finder's fees, broker warrants, advisory fees, tail terms, expense caps or corporate finance fees, and whether any insider, related party or strategic investor issues are already visible. If those points are vague at the outset, they tend to get expensive later.

Conflicts of interest and related-party relationships should also be front and centre. If the use of proceeds will benefit an affiliate, related issuer or overlapping management team, the disclosure should be conspicuous in the subscription materials and any marketing deck. This is not the place for hide-the-ball drafting.

A detailed closing agenda is the backbone of execution. It should map securities law timing, exchange timing, board timing, investor document timing, transfer-agent timing and settlement timing into one document. A closing agenda that treats those as separate tracks is how deals miss deadlines.

Best practice is to have investor names, registration instructions, beneficial owner details, exemption support and signature pages substantially locked down at least two to three business days before closing. That gives counsel time to send a consolidated treasury direction, lets the transfer agent QA the paper, and gives brokers and cages enough runway to do their part. If subscriptions are still moving materially on the morning of closing, the deal is already in the danger zone.

A treasury direction is the issuance blueprint sent to the transfer agent. At a practical level, it should capture the registered name and address, security type and number, legends, U.S. person status, any ITF or TR registration convention, and the relevant issued and outstanding counts needed to reconcile the register and the closing forms.

Treasury directions can also become an authority problem, not just an issuance problem. Depending on the transfer agent's file and the issuer's signing authorities, the direction may need to be executed by two current officers whose authority is reflected in an up-to-date incumbency certificate or signing resolution. If that officer information is stale, the problem often surfaces at exactly the wrong time and can delay closing.

This is also the point where timing meets reality. In parallel with the treasury direction, issuer's counsel should be notifying brokers and cages of the planned closing date, the expected delivery mechanics and the trust or issuer account for the incoming wire. Even where everyone is notified in advance, some brokers will not release cash until they have confirmed receipt of the securities into the client account. That can push actual cash receipt one or two business days past the nominal closing date.

If the financing is tied to a same-week acquisition payment, option payment, royalty closing, QT step or RTO milestone, that lag matters a lot.

Issuers and underwriters relying on NI 45-106 exemptions generally need to file Form 45-106F1 within 10 days of the distribution, subject to the different timing that applies in some crowdfunding and investment fund contexts. The filing is now made through SEDAR+, and the schedules need to be handled carefully.

Schedule 1 contains confidential purchaser information. Schedule 2 captures confidential director, executive officer, promoter and control person information where required. Those schedules are not casual appendices. They need to reconcile to the cap table, the subscription materials and the main body of the form. Modified or mangled templates are exactly the kind of thing that gets re-filings and avoidable pain.

Exchange filings do not stop at launch. On the TSXV, final private placement information needs to be filed and updated so the Exchange can issue its bulletin. On the CSE, the final Form 9 and Certificate of Compliance need to be posted and closing materials need to be delivered. On the TSX, any conditions in the TSX review letter or approval process need to be satisfied and any updates to Form 11 need to be made cleanly. On the TSXV, that also means dealing with the final or amended Form 4B.

Where new insiders, control-sensitive placees or corporate placees are involved, the exchange side can remain live after closing. This is another reason why the placee list needs to be managed deliberately through closing.

Reporting issuers also need to make sure the financing is reflected properly in their continuous disclosure record. That usually means launch disclosure, closing disclosure, hold period disclosure, fee disclosure and, where applicable, material change analysis. Investors crossing early warning thresholds need their own disclosure package on their own timetable.

The basic principle is consistency. Exchange forms, Form 45-106F1, news releases, material change reports and insider or early warning filings should tell the same story. When those documents do not line up, it creates avoidable regulatory and exchange risk.

A private placement is often one leg of a larger stool. It may be funding a mining option payment, bridging a royalty acquisition, preserving a shell ahead of a TSXV qualifying transaction (QT) or a CSE reverse takeover (RTO), supporting a change of business, or backstopping a strategic pivot. That means the financing terms cannot be reviewed in isolation.

Three patterns come up repeatedly:

• A junior mining issuer wants enough money to fund an option payment and working capital, but not so much discounted paper that the cap table gets ugly or a new control problem appears.
• A shell or sponsor group wants to keep the vehicle clean enough for a later QT or RTO, which means being disciplined about pricing, proceeds, insider participation and not over-engineering the paper too early.
• A public issuer is doing a financing alongside an acquisition, royalty, SAFE or other strategic transaction, which means the use of proceeds, exchange disclosure and transaction sequencing all have to match across the full deal stack.

That is why experienced issuers do not ask only, can we close the private placement? They ask, can we close the private placement without boxing ourselves in for the next move?

Understanding where private placements sit relative to bought deals and other underwritten offerings still matters. Best-efforts brokered private placements leave market risk largely with the issuer. Firm-commitment and bought-deal structures shift more risk to the underwriter and are more common in public offerings. The practical point is that private placements can be faster and more flexible, but once the deal gets large enough, the question is not just whether a private placement is available. It is whether it is still the best instrument for the job.

Investor decks and marketing materials are themselves regulated instruments in some contexts. They should align with the issuer's disclosure record, avoid selective disclosure of material non-public information, and contain the right cautionary language and statutory rights language where required. A slick deck that gets ahead of the issuer's actual disclosure record is not helping the financing. It is creating liability.

This is one of the least glamorous and most expensive places to get lazy. Exchanges and securities regulators do look at how net proceeds are actually used against what was disclosed in the subscription package, term sheet, news releases and other filings.

If the disclosure said project spend, do not quietly use the money to pay down related-party debt, backfill old liabilities or fund compensation that was never disclosed as part of the use of proceeds story. If the facts change materially after closing, update the disclosure properly. Vague working capital language is not a universal hall pass. Private placements reward disciplined preparation and punish casual execution.

Pulling the above together, the recurring pressure points are usually the same:

• Start with the investor map, not just the raise target. The exemption mix determines the investor pool, the paper and the post-closing obligations.
• Model control drift early. Track insider status, early warning issues, exchange categories, and who may become strategically important after closing.
• Treat fee economics as part of structure. Cash commissions, finder's fees, broker warrants and dealer paper affect dilution, disclosure, net proceeds and sometimes future leverage.
• Run one integrated timeline. Exchange filings, board approvals, subscriptions, treasury direction work, transfer agent preparation and settlement mechanics need to live on one closing plan.
• Lock down names and registrations early. Most ugly settlement problems are boring problems that should have been solved two days earlier.
• Assume settlement friction. Build for broker-specific registration quirks, cage handling and delayed wires, especially where the financing is tied to another transaction.
• Keep the cap table evergreen. If the investor list changes, the percentages change, and that can change the legal analysis.
• Match the use of proceeds to the disclosure. Regulators are much less amused by creative re-allocation than issuers sometimes assume.

Canadian private placements are not just a securities law exercise. They are a structure problem, a control problem, a timing problem and a closing problem, all at once. The legal framework matters, obviously. But the deals that go sideways usually do so for more mundane reasons: the exemption analysis was lazy, insider participation changed the approval path, the cap table was not being tracked properly, legends or registrations were wrong, fee economics were left fuzzy, or settlement mechanics were treated like back-office trivia until closing day.

When done properly, private placements are one of the most flexible tools in Canadian capital formation. That is why serious participants do not treat them as commodity paper. Done casually, they can create control drift, disclosure problems, delayed closings and expensive cleanup.

If you are structuring a financing and want counsel who has actually lived the cap table problems, the exchange timing friction, the settlement plumbing and the post-closing cleanup, that is the work I do. Ghosh Law advises issuers, funds and deal teams across the full private placement lifecycle, from structure and exchange process to closing execution and post-closing compliance.

• Securities Act (Ontario), the Canadian Securities Administrators and the Ontario Securities Commission, including NI 45-106, NI 45-102, NI 51-102, NI 62-103, NI 62-104, NI 24-101, NI 55-104, Form 45-106F1 and related exempt distribution, early warning and insider reporting guidance.
• TSX Venture Exchange Corporate Finance Manual, including Policy 4.1, Policy 5.1, Policy 3.2 and Form 4B.
• TSX Company Manual, including Section 607, Form 11 and Form 11A.
• Canadian Securities Exchange Policy 6, Form 9 and related hold and notice mechanics.
• Coordinated Blanket Order 45-935 and related CSA / OSC notices regarding the Listed Issuer Financing Exemption.